

U.S. PATENT DOCUMENTS						
Evaminar	04-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Examiner initiats*	Cite No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
m	1.	US-4,106,992	08-15-1978	Vairel et al.		

Attorney Docket Number

544112000200

		FOREIG	GN PATENT	DOCUMENTS	***	
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pagas, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document		<b>™</b>
or	2.	WO-2005/058243-A2	06-30-2005	Proteomtech Inc.		
07	3.、	WO-2005/058930-A2	06-30-2005	Proteomtech Inc.		

"EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
n	4.	Fahey, E.M. et al. (2000). "Refolding and Purification of a Urokinase Plasminogen Activator Fragment by Chromatography," <i>Journal of Chromatography B</i> 737:225-235.	
or	5.	Hua, Z-C. et al. (1996). "Renaturation of Recombinant Human Pro-Urokinase Expressed in Escherichia coli," Biochemical and Biophysical Research Communications 220:131-136.	
or	6.	Hui, Z. et al. (2001). "In Vitro Renaturation of Recombinant Human Pro-Urokinase Expressed in Escherichia coli," Chinese Medical Journal 114(2):186-190.	
or	7.	International Search Report mailed on July 25, 2005 for PCT Application No. PCT/US04/11792 filed April 16, 2004, 4 pages.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Examiner Signature Considered

pa-1004886

Sheet

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application Number 10/825,911 April 16, 2004 Filing Date First Named Inventor Xinli LIN Art Unit 1652

Complete if Known

(Use as many sheets as necessary)

Sheet

I. Chowdhury Examiner Name R. Prouty 544112000200 Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	
Examiner		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
n	1.	US-2001/0044521-A1	11-22-2001	Lin	
02	2.	US-2003/0170242-A1	09-11-2003	Li et al.	
00/	3.	US-2003/0199676-A1	10-23-2003	Lin	
0		US-4;511,503	04-16-1985	Olson et al.	
or		US-4,599,197	07-08-1986	Wetzel	
or	6.	US-5,188,829-A	02-23-1993	Kobayashi et al.	
or	7. ·	US-5,219,569-A	06-15-1993	Blaber et al.	
02	8.	US-5,472,692-A	12-05-1995	Liu et al.	
or	9.	US-6,583,268-B2	06-24-2003	Lin	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
n	10.	WO-01/55174-A2	08-02-2001	Oklahoma Medical Research Foundation		П
n	11.	WO-03/039491-A2	05-15-2003	Georgetown University		
n	12.	WO-2004/094344-A2	11-04-2004	Proteomtech, Inc.		

"EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspio.gov">www.uspio.gov</a> or MPEP 901.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
or	13.	Adams, D.S. et al. (May 5, 1991). "A Synthetic DNA Encoding a Modified Human Urokinase Resistant to Inhibition by Serum Plasminogen Activator Inhibitor," <i>The Journal of Biological Chemistry</i> 266(13):8476-8482.	•
ge	-14.	Liu, JN. et al. (2002). "Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis," Circ. Res. 90:757-763.	
n	15.	Orsini, G. et al. (1991). "Efficient Renaturation And Fibrinolytic Properties Of Prourokinase And A Deletion Mutant Expressed In <i>Escherichia Coli</i> As Inclusion Bodies," <i>Eur. J. Biochem.</i> 195:691-697.	
n	16.	Quax, P.H.A. et al. (1998). "Binding of Human Urokinase-Type Plasminogen Activator to Its Receptor," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 18:693-701.	
n	17.	Sun, Z. et al. (September 19, 1997). "Identification of a Flexible Loop region (297-313) of Urokinase-type Plasminogen Activator, Which Helps Determine Its Catalytic Activity," <i>The Journal of Biological Chemistry</i> 272(38):23818-23823.	
n	18.	Tang, W. et al. (1997). "An Efficient System for Production of Recombinant Urokinase-Type Plasminogen Activator," <i>Protein Expression and Purification</i> 11:279-283.	
n	19.	Wang, P. et al. (2000). "Catalytic and Fibrinolytic Properties of Recombinant Urokinase Plasminogen Activator from <i>E. coli</i> , Mammalian, and Yeast Cells," <i>Thrombosis Research</i> 100:461-467.	

Examiner Signature	Dale	al (for)	M	Date Considered	11/1525

pa-974301

## ALTERNATIVE TO PTO/SB/08a/b (06-03)

Sul	bstitute for form 1449/PT	0		Complete if Known		
			•	Application Number	10/825,911	
11	NFORMATIC	)N DI	SCLOSURE	Filing Date	April 16, 2004	
S	TATEMENT	BY	APPLICANT	First Named Inventor	Xinli LIN	
				Art Unit	1652	
	(Use as many	sheets as	i,necess ary)	Examiner Name	R. Prouty I- Chowdhary	
Sheet	2	of	2	Attorney Docket Number	544112000200	

p 20.	Winkler, M.E. et al. (1986). "Purification and Characterization of Recombinant Single-Chain	
0V	Urokinase Produced in Escherichia coli," Biochemistry 25:4041-4045.	

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature pa- 974301 Date Considered

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.